Device Trial Radar · NCT07281391
IOP Reduction in Pigmentary Glaucoma Using DSLT
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Mar 19, 2026
Primary completion
Apr 1, 2027
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Mann Eye InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sengi
- First posted
- Dec 15, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
Conditions
- Pigmentary Dispersion Syndrome
- Pigmentary Dispersion Glaucoma
Interventions
Voyager DSLTDevice
DSLT is an innovative adaptation of traditional SLT. Rather than using a gonioscopic lens, DSLT applies laser energy directly through the limbus to the trabecular meshwork in a few seconds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean washed-out IOP change post-DSLT compared to washed-out baseline IOPTime frame: 6 months post-DSLT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mann Eye Institute
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.